中国组织工程研究 ›› 2018, Vol. 22 ›› Issue (21): 3281-3285.doi: 10.3969/j.issn.2095-4344.0895

• 骨髓干细胞 bone marrow stem cells •    下一篇

神经生长因子经鼻脑靶向联合骨髓干细胞自体动员治疗重型颅脑损伤

王君毅1,步星耀2,顾建军3,胡 森1,王帮庆2,高玉帅2   

  1. 1河南中医药大学基础医学院,河南省郑州市 450046;2河南省人民医院神经外科,河南省郑州市 450006;3河南省人民医院介入科,河南省郑州市 450006
  • 修回日期:2018-05-25 出版日期:2018-07-28 发布日期:2018-07-28
  • 通讯作者: 步星耀,博士后,主任医师,教授,硕士生导师,河南省人民医院神经外科,河南省郑州市 450006
  • 作者简介:王君毅,男,1984年生,河南省商水县人,汉族,河南中医药大学在读硕士,主要从事神经系统疾病研究。
  • 基金资助:

    河南省科技攻关项目(122102310151,201601016);河南医学科技创新人才工程项目(2011020120)

Interventions for severe craniocerebral injury by nasal administration of nerve growth factor combined with bone marrow stem cell mobilization

Wang Jun-yi1, Bu Xing-yao2, Gu Jian-jun3, Hu Sen1, Wang Bang-qing2, Gao Yu-shuai2   

  1. 1College of Basic Medicine of Henan University of Traditional Chinese Medicine, Zhengzhou 450046, Henan Province, China; 2Department of Neurology, 3Department of Intervention, Henan Provincial People’s Hospital, Zhengzhou 450006, Henan Province, China
  • Revised:2018-05-25 Online:2018-07-28 Published:2018-07-28
  • Contact: Bu Xing-yao, M.D., Chief physician, Professor, Master’s supervisor, Department of Neurology, Henan Provincial People’s Hospital, Zhengzhou 450006, Henan Province, China
  • About author:Wang Jun-yi, Master candidate, College of Basic Medicine of Henan University of Traditional Chinese Medicine, Zhengzhou 450046, Henan Province, China
  • Supported by:

    the Science and Technology Research Project of Henan Province, No. 122102310151, 201601016; the Medical Innovation Talent Project of Henan Province, No. 2011020120

摘要:

文章快速阅读:

文题释义:
骨髓干细胞:
是骨髓中的造血结构性和功能性支持细胞,它具有极强自我更新能力和多项分化潜能,参与组织细胞的修复及替代,以及促进多种器官改建或受伤后的修复。在治疗神经损伤时它可以分化为神经细胞,同时分泌多种生长因子并合成胶原蛋白、纤维连接蛋白等细胞外基质,进而促进神经纤维再生及功能恢复。
经鼻脑靶向:是经鼻腔给予具有脑靶向性的药物,经鼻腔给药使药物利用度高,使用便捷,能够避免药物对胃肠道的刺激及肝脏首过效应,药物经鼻能够穿过血脑屏障迅速进入中枢神经系统到达药物靶点,对治疗脑部损伤有良好疗效。

 

摘要
背景:
经鼻脑靶向给药是一种新型给药方法,可以绕开血脑屏障,直接作用于中枢神经系统,不仅具有良好的脑靶向性,还具有无创、快捷的优点。研究表明神经生长因子联合骨髓干细胞动员治疗脑损伤有协同作用。
目的:观察神经生长因子经鼻脑靶向联合自体骨髓干细胞动员及综合康复治疗重型颅脑损伤的疗效。
方法:①选择河南省人民医院神经外科收治的资料完整的创伤性脑损伤患者78例,根据治疗方案不同分为2组:对照组39例采用神经生长因子肌肉注射,1次/d,持续28 d,联合自体骨髓干细胞动员治疗;观察组39例采用神经生长因子经鼻脑靶向滴入,1次/d,连续给药28 d,联合自体骨髓干细胞动员治疗;②自体骨髓干细胞动员治疗方案:在脑损伤1周后皮下注射重组人粒细胞集落刺激因子或重组人巨噬细胞集落刺激因子,每3 d 1次,2种交替,同时配合辛伐他汀片10 mg/d口服,连续28 d;③出院后2组患者继续行神经生长因子治疗3个月。
结果与结论:①患者治疗28 d时,观察组神经功能缺损评分略低于对照组,差异无显著性意义(t=0.429,P > 0.05);②治疗3个月后NIHSS评分,观察组显著优于对照组(t=7.176,P < 0.05);③格拉斯哥评分(GOS)观察组明显高于对照组(P < 0.05);④两组患者治疗与随访期间均未出现明显不良反应。⑤结果说明,神经生长因子经鼻脑靶向联合自体骨髓干细胞动员及康复治疗能有效促进重型颅脑损伤的修复,显著改善患者神经功能。

中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
ORCID:
0000-0002-6861-9075(王君毅)

关键词: 颅脑损伤, 神经生长因子, 经鼻脑靶向, 骨髓干细胞, 康复治疗, 干细胞

Abstract:

BACKGROUND: Nasal administration is a new route of administration in which drugs can bypass the blood-brain barrier and act directly on the central nervous system. It not only has good brain targeting but also has the advantages of being non-invasive and convenient. Studies have shown that nerve growth factor (NGF) combined with bone marrow stem cell (BMSC) mobilization has a synergistic effect on brain injury.
OBJECTIVE: To observe the therapeutic effect of NGF combined with autologous BMSC mobilization via nasal administration and comprehensive rehabilitation for severe craniocerebral injury.
METHODS: Seventy-eight patients with traumatic brain injury from the Department of Neurosurgery of Henan Provincial People’s Hospital were selected and treated with NGF intramuscular injection (once a day, for continuous 28 days) combined with BMSC mobilization and comprehensive rehabilitation therapy as control group (n=39) or treated with NGF through the nasal administration (once a day, for continuous 28 days) combined with BMSC and comprehensive rehabilitation treatment as observation group (n=39). Therapeutic schedule for autologous BMSC mobilization was as follows: subcutaneous injection of recombinant human granulocyte colony-stimulating factor or recombinant human macrophage colony-stimulating factor alternately at 1 week after brain injury, once every 3 days, and oral administration of simvastatin tablets, 10 mg per day, for continuous 28 days. Two groups of patients continued to be treated with NGF for 3 months after discharge.
RESULTS AND CONCLUSION: At 28 days after treatment, the neurologic defect score in the observational group was slightly lower than that in the control group, but there was no significant difference between the two groups (t=0.429, P > 0.05). At 3 months after treatment, the score on the National Institutes of Health Stroke Scale was significantly better in the observational group than the control group (t=7.176, P < 0.05), and the score on the Glasgow Coma Scale Glasgow was also significantly higher in the observational group than the control group (P < 0.05). No obvious adverse event occurred in the two groups during the treatment and follow-up. To conclude, nasal administration of NGF combined with autologous BMSC mobilization and rehabilitation therapy can effectively promote the repair of severe craniocerebral injury and significantly improve the neurological function of the patients.

中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程

Key words: Craniocerebral Trauma, Nerve Growth Factor, Molecular Targeted Therapy, Mesenchymal Stem Cells, Tissue Engineering

中图分类号: